HSTM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HealthStream Inc (HSTM) is not a strong buy for a beginner, long-term investor at this time. The stock lacks significant positive catalysts, has bearish technical indicators, and recent financial performance shows declining profitability. While the company has a positive recognition in its sector, insider selling and neutral hedge fund activity suggest caution. Analysts have also lowered price targets, reflecting a cautious outlook.
The MACD is positive and expanding, indicating mild bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a downward trend. The stock is trading near its resistance level (R1: 21.555), limiting immediate upside potential.
HealthStream's Virsys12 was recognized as a Leader in the IDC MarketScape 2025-2026 U.S. Provider Data Management Vendor Assessment, which highlights the company's strong position in provider data management solutions.
Insider selling has increased by 146.37% over the last month, and hedge funds remain neutral. Analysts have lowered price targets twice in recent months, citing an uncertain healthcare environment and concerns about AI disintermediation. Additionally, financial performance shows significant declines in net income and EPS.
In Q4 2025, revenue increased by 7.37% YoY to $79.71M, but net income dropped by 48.17% YoY to $2.53M. EPS declined by 43.75% YoY to $0.09, and gross margin fell by 4.07% YoY to 49.96%. These metrics indicate revenue growth but declining profitability.
Canaccord has lowered the price target twice recently, first from $28 to $25 and then from $25 to $21, maintaining a Hold rating. Analysts have expressed concerns about the uncertain healthcare environment and potential AI disruptions, though management has addressed these concerns positively.
